Researchers concluded in a study that artificial intelligence improves the ability of doctors to identify breast cancer patients who can benefit from drug therapy targeting protein Hair 2 in cancer cells.
Among these drugs (Einherto) produced by Astrazinica, and the patient benefits from it even when the target protein levels are very low in its cancer cells.
However, it is possible, to be difficult to discover low or very low levels of protein, which leads to the diagnosis of some cases as a protein negative.
The data of the American National Cancer Institute suggests that between 50 to 60 percent of breast cancer patients, their cancer cells contain low levels of protein Hair 2.
The researchers said in the study, which will be presented at the American Association for Clinical Oncology, that the desire to use Enharyo to treat breast cancer has greatly exceeded the ability to identify patients from which you will benefit from certainty.
Funded by Astrazinica, the researchers worked with Mindbick to develop a training program to help pathology specialists to evaluate the protein heer 2 levels in breast cancer cells.
“Our study provides the first evidence that includes multiple nationalities that artificial intelligence can help enhance accuracy” in determining the levels of protein Hair 2 (positive, negative, and low), adding that this may “block very important diagnostic gaps and allow more Patients get new treatments.
She noted that “until recently, these options were not available to most of these patients.”
And (Hair 2) or (the future of the human growth factor in humans 2) is part of a family of receptors that help cells to respond to the signals that you command to grow and divide. It is involved in natural cellular processes, but when it becomes abnormal (museum), the cell growth can lead to an uncontrolled growth, which contributes to the development of cancer.